English

BARINTHUS BIOTHERAPEUTICS PLC

EDGAR

VACC Quarterly report (10-Q) · filed 2026-08-06

Annual consolidated revenue for 2025: about USD 0, using the latest reported figures. The previous period, 2024, was about USD 14.97M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2025 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-4.24 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -47979000 USD Source
Operating Cash Flow: -43737000 USD Source

Free cash flow

-4.24 million USD

2025 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -47979000 USD Source
Operating Cash Flow: -43737000 USD Source
Capital Expenditure: 37000 USD Source
Capital Expenditure: 37000 USD Source

Cash and cash equivalents: 59.3 million USD 2026-06-30 Source
Exact value

59295000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 40.8 million shares 2026-06-30 Source
Exact value

40848893 shares

Reported share-count change

1.24% · 500 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

40348665 shares · 2025-06-30· Source
40848893 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-41.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -14566000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -66428000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -55338000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -5531000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -10580000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-26.4 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -43737000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -33011000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -47979000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -43737000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -3366000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -11457000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -3366000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

0 USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 37000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 37000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 37000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 37000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-26.4 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -43737000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -33011000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -47979000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -43737000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -3366000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -11457000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -3366000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 37000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 37000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 37000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 37000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2025-12-31
Operating income: 4 of 11 periods available· newest 2025-12-31
Net income: 4 of 11 periods available· newest 2025-12-31
Operating cash flow: 4 of 11 periods available· newest 2025-12-31
Capital expenditure: 4 of 11 periods available· newest 2025-12-31
Total assets: 4 of 11 periods available· newest 2025-12-31
Total liabilities: 4 of 11 periods available· newest 2025-12-31
Current assets: 4 of 11 periods available· newest 2025-12-31
Current liabilities: 4 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 4 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-100%

Prior period

USD 14.97 million

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 14969000 = -14969000 USD

14969000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · BARINTHUS BIOTHERAPEUTICS PLC · 2025-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Year-over-year change in Revenue: -14969000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1592032 Filing: 000182818526000012 Input fundies:Revenue: 14969000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1592696 Filing: 000182818526000012
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 5.35 million

Prior period

−USD 61.07 million

2024-01-01 – 2024-12-31
Current period

−USD 66.43 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-66428000 − -61074000 = -5354000 USD

-61074000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-66428000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · BARINTHUS BIOTHERAPEUTICS PLC · 2025-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Year-over-year change in Net income: -5354000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -66428000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1934229 Filing: 000182818526000012 Input fundies:NetIncome: -61074000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1935098 Filing: 000182818526000012
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 19.04 million

Prior period

−USD 28.94 million

2024-01-01 – 2024-12-31
Current period

−USD 47.98 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-47979000 − -28940000 = -19039000 USD

-28940000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-47979000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · BARINTHUS BIOTHERAPEUTICS PLC · 2025-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Year-over-year change in Operating cash flow: -19039000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -47979000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1768896 Filing: 000182818526000012 Input fundies:OperatingCashFlow: -28940000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1769792 Filing: 000182818526000012
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-95.9%

Prior period

USD 892,000

2024-01-01 – 2024-12-31
Current period

USD 37,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

37000 − 892000 = -855000 USD

892000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
37000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · BARINTHUS BIOTHERAPEUTICS PLC · 2025-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Year-over-year change in Capital expenditure: -855000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 37000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1773079 Filing: 000182818526000012 Input fundies:CapitalExpenditure: 892000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1773636 Filing: 000182818526000012
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 0
Operating costs Derived USD 70.56 million
Operating income −USD 70.56 million
Tax, interest and other Derived −USD 4.13 million
Net income −USD 66.43 million

Cash

Operating cash flow −USD 47.98 million
Capital expenditure USD 37,000
Free cash flow Derived −USD 48.02 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2022 Operating loss: operating costs were 109% of revenue.
2023 Operating loss: operating costs were 10,563% of revenue.
2024 Operating loss: operating costs were 554% of revenue.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2022 2022-01-01 – 2022-12-31	44703000	48744000 Derived	-4041000	-9383000 Derived	5342000	-20569000 Derived	Source 2022-01-01 – 2022-12-31: 44703000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -4041000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: 5342000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -14431000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 6138000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	802000	84716000 Derived	-83914000	-10567000 Derived	-73347000	-56338000 Derived	Source 2023-01-01 – 2023-12-31: 802000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -83914000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -73347000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -50925000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 5413000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	14969000	82939000 Derived	-67970000	-6896000 Derived	-61074000	-29832000 Derived	Source 2024-01-01 – 2024-12-31: 14969000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -67970000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -61074000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -28940000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 892000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	0	70555000 Derived	-70555000	-4127000 Derived	-66428000	-48016000 Derived	Source 2025-01-01 – 2025-12-31: 0 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -70555000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -66428000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -47979000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 37000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Revenue	44703000	Revenue: 44703000 Open source
20232023-12-31	Revenue	802000	Revenue: 802000 Open source
20242024-12-31	Revenue	14969000	Revenue: 14969000 Open source
20252025-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Year over year	No prior comparable period	Revenue: 44703000 Open source
20232023-12-31	Year over year	-98.2%	Revenue: 802000 Open source Revenue: 44703000 Open source
20242024-12-31	Year over year	1,766.5%	Revenue: 14969000 Open source Revenue: 802000 Open source
20252025-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 14969000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -454.1% 2024

Net margin -408% 2024

Free cash flow margin -199.3% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Operating margin	-9%	Operating Income: -4041000 Open source Revenue: 44703000 Open source
20232023-12-31	Operating margin	-10,463.1%	Operating Income: -83914000 Open source Revenue: 802000 Open source
20242024-12-31	Operating margin	-454.1%	Operating Income: -67970000 Open source Revenue: 14969000 Open source
20252025-12-31	Operating margin	Not reported	Operating Income: -70555000 Open source Revenue: 0 Open source
20222022-12-31	Net margin	11.9%	Net Income: 5342000 Open source Revenue: 44703000 Open source
20232023-12-31	Net margin	-9,145.5%	Net Income: -73347000 Open source Revenue: 802000 Open source
20242024-12-31	Net margin	-408%	Net Income: -61074000 Open source Revenue: 14969000 Open source
20252025-12-31	Net margin	Not reported	Net Income: -66428000 Open source Revenue: 0 Open source
20222022-12-31	Free cash flow margin	-46%	Revenue: 44703000 Open source Operating Cash Flow: -14431000 Open source Capital Expenditure: 6138000 Open source
20232023-12-31	Free cash flow margin	-7,024.7%	Revenue: 802000 Open source Operating Cash Flow: -50925000 Open source Capital Expenditure: 5413000 Open source
20242024-12-31	Free cash flow margin	-199.3%	Revenue: 14969000 Open source Operating Cash Flow: -28940000 Open source Capital Expenditure: 892000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -47979000 Open source Capital Expenditure: 37000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -48M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Operating cash flow	-14431000	Operating Cash Flow: -14431000 Open source
20232023-12-31	Operating cash flow	-50925000	Operating Cash Flow: -50925000 Open source
20242024-12-31	Operating cash flow	-28940000	Operating Cash Flow: -28940000 Open source
20252025-12-31	Operating cash flow	-47979000	Operating Cash Flow: -47979000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -48M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20222022-12-31	Free cash flow	-20569000	Operating Cash Flow: -14431000 Open source Capital Expenditure: 6138000 Open source
20232023-12-31	Free cash flow	-56338000	Operating Cash Flow: -50925000 Open source Capital Expenditure: 5413000 Open source
20242024-12-31	Free cash flow	-29832000	Operating Cash Flow: -28940000 Open source Capital Expenditure: 892000 Open source
20252025-12-31	Free cash flow	-48016000	Operating Cash Flow: -47979000 Open source Capital Expenditure: 37000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

24.3% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Liabilities / assets	10%	Total Liabilities: 27004000 Open source Total Assets: 270205000 Open source
20232023-12-31	Liabilities / assets	12.8%	Total Liabilities: 27511000 Open source Total Assets: 214506000 Open source
20242024-12-31	Liabilities / assets	18.8%	Total Liabilities: 30192000 Open source Total Assets: 160327000 Open source
20252025-12-31	Liabilities / assets	24.3%	Total Liabilities: 23877000 Open source Total Assets: 98169000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.77× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20222022-12-31	Current assets / current liabilities	17.4×	Current Assets: 213041000 Open source Current Liabilities: 12242000 Open source
20232023-12-31	Current assets / current liabilities	12.45×	Current Assets: 156905000 Open source Current Liabilities: 12598000 Open source
20242024-12-31	Current assets / current liabilities	8.03×	Current Assets: 125742000 Open source Current Liabilities: 15657000 Open source
20252025-12-31	Current assets / current liabilities	7.77×	Current Assets: 77790000 Open source Current Liabilities: 10018000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2022 2022-01-01 – 2022-12-31	USD 5.34 million Exact value Exact value: 5342000 USD 2022-01-01 – 2022-12-31: 5342000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BARINTHUS BIOTHERAPEUTICS PLC · 2022-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Net Income: 5342000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: 5342000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000011/brns-20231231.htm#1906004 Filing: 000182818524000011 The citation records this snapshot. The page link may show a newer release later.	−USD 14.43 million Exact value Exact value: -14431000 USD 2022-01-01 – 2022-12-31: -14431000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BARINTHUS BIOTHERAPEUTICS PLC · 2022-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Operating Cash Flow: -14431000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14431000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000011/brns-20231231.htm#1761864 Filing: 000182818524000011 The citation records this snapshot. The page link may show a newer release later.	USD 6.14 million Exact value Exact value: 6138000 USD 2022-01-01 – 2022-12-31: 6138000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BARINTHUS BIOTHERAPEUTICS PLC · 2022-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Capital Expenditure: 6138000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6138000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000011/brns-20231231.htm#1765823 Filing: 000182818524000011 The citation records this snapshot. The page link may show a newer release later.	−USD 20.57 million Calculation and evidence -14431000 − 6138000 USD Exact free cash flow: -20569000 USD 2022-01-01 – 2022-12-31: -14431000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 6138000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BARINTHUS BIOTHERAPEUTICS PLC · 2022-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Free cash flow: -20569000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14431000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000011/brns-20231231.htm#1761864 Filing: 000182818524000011 Input fundies:CapitalExpenditure: 6138000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818524000011/brns-20231231.htm#1765823 Filing: 000182818524000011 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 73.35 million Exact value Exact value: -73347000 USD 2023-01-01 – 2023-12-31: -73347000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BARINTHUS BIOTHERAPEUTICS PLC · 2023-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Net Income: -73347000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -73347000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000021/brns-20241231.htm#1855495 Filing: 000182818525000021 The citation records this snapshot. The page link may show a newer release later.	−USD 50.93 million Exact value Exact value: -50925000 USD 2023-01-01 – 2023-12-31: -50925000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BARINTHUS BIOTHERAPEUTICS PLC · 2023-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Operating Cash Flow: -50925000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -50925000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000021/brns-20241231.htm#1693569 Filing: 000182818525000021 The citation records this snapshot. The page link may show a newer release later.	USD 5.41 million Exact value Exact value: 5413000 USD 2023-01-01 – 2023-12-31: 5413000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BARINTHUS BIOTHERAPEUTICS PLC · 2023-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Capital Expenditure: 5413000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5413000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000021/brns-20241231.htm#1696245 Filing: 000182818525000021 The citation records this snapshot. The page link may show a newer release later.	−USD 56.34 million Calculation and evidence -50925000 − 5413000 USD Exact free cash flow: -56338000 USD 2023-01-01 – 2023-12-31: -50925000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 5413000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BARINTHUS BIOTHERAPEUTICS PLC · 2023-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Free cash flow: -56338000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -50925000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000021/brns-20241231.htm#1693569 Filing: 000182818525000021 Input fundies:CapitalExpenditure: 5413000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000021/brns-20241231.htm#1696245 Filing: 000182818525000021 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 61.07 million Exact value Exact value: -61074000 USD 2024-01-01 – 2024-12-31: -61074000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BARINTHUS BIOTHERAPEUTICS PLC · 2024-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Net Income: -61074000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -61074000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1935098 Filing: 000182818526000012 The citation records this snapshot. The page link may show a newer release later.	−USD 28.94 million Exact value Exact value: -28940000 USD 2024-01-01 – 2024-12-31: -28940000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BARINTHUS BIOTHERAPEUTICS PLC · 2024-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Operating Cash Flow: -28940000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -28940000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1769792 Filing: 000182818526000012 The citation records this snapshot. The page link may show a newer release later.	USD 892,000 Exact value Exact value: 892000 USD 2024-01-01 – 2024-12-31: 892000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BARINTHUS BIOTHERAPEUTICS PLC · 2024-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Capital Expenditure: 892000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 892000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1773636 Filing: 000182818526000012 The citation records this snapshot. The page link may show a newer release later.	−USD 29.83 million Calculation and evidence -28940000 − 892000 USD Exact free cash flow: -29832000 USD 2024-01-01 – 2024-12-31: -28940000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 892000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BARINTHUS BIOTHERAPEUTICS PLC · 2024-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Free cash flow: -29832000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -28940000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1769792 Filing: 000182818526000012 Input fundies:CapitalExpenditure: 892000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1773636 Filing: 000182818526000012 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 66.43 million Exact value Exact value: -66428000 USD 2025-01-01 – 2025-12-31: -66428000 USD Inspect Net Income Open source Share or cite Citation for Net Income · BARINTHUS BIOTHERAPEUTICS PLC · 2025-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Net Income: -66428000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -66428000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1934229 Filing: 000182818526000012 The citation records this snapshot. The page link may show a newer release later.	−USD 47.98 million Exact value Exact value: -47979000 USD 2025-01-01 – 2025-12-31: -47979000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · BARINTHUS BIOTHERAPEUTICS PLC · 2025-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Operating Cash Flow: -47979000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -47979000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1768896 Filing: 000182818526000012 The citation records this snapshot. The page link may show a newer release later.	USD 37,000 Exact value Exact value: 37000 USD 2025-01-01 – 2025-12-31: 37000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · BARINTHUS BIOTHERAPEUTICS PLC · 2025-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Capital Expenditure: 37000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 37000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1773079 Filing: 000182818526000012 The citation records this snapshot. The page link may show a newer release later.	−USD 48.02 million Calculation and evidence -47979000 − 37000 USD Exact free cash flow: -48016000 USD 2025-01-01 – 2025-12-31: -47979000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 37000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · BARINTHUS BIOTHERAPEUTICS PLC · 2025-12-31 BARINTHUS BIOTHERAPEUTICS PLC (edgar:1828185) Free cash flow: -48016000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T09:32:59Z Snapshot: 2e167c544acd282b1ed83fd55a50ba564bc60fa7bc814e8250bdebe50baf9663 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1828185?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -47979000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1768896 Filing: 000182818526000012 Input fundies:CapitalExpenditure: 37000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000012/brns-20251231.htm#1773079 Filing: 000182818526000012 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

28 filings · 2,509 latest values · 2,509 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001828185, 1828185, VACC, edgar:1828185

Also known as BARINTHUS BIOTHERAPEUTICS PLC, Barinthus Biotherapeutics plc., VACCITECH PLC, Vaccitech Ltd, Vaccitech plc

BARINTHUS BIOTHERAPEUTICS PLC

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation